News headlines about Dicerna Pharmaceuticals (NASDAQ:DRNA) have trended positive recently, Alpha One Sentiment Analysis reports. Alpha One, a service of Accern, ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned headlines about the biopharmaceutical company an impact score of 59 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected AlphaOne’s scoring:
- Somewhat Favorable Media Coverage Somewhat Likely to Effect Dicerna Pharmaceuticals (DRNA) Stock Price (americanbankingnews.com)
- Dicerna Pharmaceuticals Inc (DRNA) Stake Maintained by Bain Capital Life Sciences Fund, L.P. (energy.einnews.com)
- Dicerna Pharmaceuticals Inc (DRNA) Price Target Lowered to $5.00 at HC Wainwright (americanbankingnews.com)
- Dicerna Pharmaceuticals Inc (DRNA) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
A number of equities research analysts have recently commented on the company. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. HC Wainwright lowered their target price on Dicerna Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, April 10th. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 target price (down from $8.00) on shares of Dicerna Pharmaceuticals in a research note on Sunday, April 2nd. Finally, Leerink Swann reiterated a “mkt perform” rating on shares of Dicerna Pharmaceuticals in a research note on Wednesday, February 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $5.88.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded down 1.29% during midday trading on Thursday, hitting $3.06. The stock had a trading volume of 234,937 shares. The firm’s market cap is $63.63 million. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.10. The firm has a 50 day moving average of $2.99 and a 200 day moving average of $3.19.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Thursday, March 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.05. The company earned $0.13 million during the quarter. Equities research analysts predict that Dicerna Pharmaceuticals will post ($2.78) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was originally published by WKRB News and is the property of of WKRB News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at http://www.wkrb13.com/markets/2065657/dicerna-pharmaceuticals-drna-earning-positive-press-coverage-report-shows.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065657/dicerna-pharmaceuticals-drna-earning-positive-press-coverage-report-shows.html
Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.